XWARBCX
Market cap103mUSD
Dec 23, Last price
85.80PLN
1D
2.75%
1Q
22.75%
IPO
145.14%
Name
Bioceltix SA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.58%
Rev. gr., 5y
%
Revenues
0k
Net income
-14m
L+53.42%
CFO
-15m
L+86.53%
Profile
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 14,307 | 9,589 | 6,187 | |||
Unusual Expense (Income) | ||||||
NOPBT | (14,307) | (9,589) | (6,187) | |||
NOPBT Margin | ||||||
Operating Taxes | (46) | 42 | ||||
Tax Rate | ||||||
NOPAT | (14,307) | (9,543) | (6,228) | |||
Net income | (13,688) 53.42% | (8,921) 102.87% | (4,398) 87.23% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 20,669 | 6,529 | 7,175 | |||
BB yield | -5.86% | -5.04% | -4.35% | |||
| Debt | ||||||
Debt current | 99 | 116 | 381 | |||
Long-term debt | 175 | 356 | 300 | |||
Deferred revenue | 2 | 1 | ||||
Other long-term liabilities | 38 | 69 | ||||
Net debt | (9,037) | (3,648) | (5,514) | |||
| Cash flow | ||||||
Cash from operating activities | (14,748) | (7,906) | (4,041) | |||
CAPEX | (458) | (352) | ||||
Cash from investing activities | (458) | (352) | 134 | |||
Cash from financing activities | 20,396 | 6,323 | 6,757 | |||
FCF | (14,555) | (9,473) | (6,627) | |||
| Balance | ||||||
Cash | 9,310 | 4,120 | 6,055 | |||
Long term investments | 139 | |||||
Excess cash | 9,310 | 4,120 | 6,194 | |||
Stockholders' equity | (13,329) | (8,308) | (9,141) | |||
Invested Capital | 23,979 | 11,854 | 15,620 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 3,919 | 3,336 | 3,162 | |||
Price | 90.00 131.96% | 38.80 -25.67% | 52.20 | |||
Market cap | 352,721 172.50% | 129,440 -21.59% | 165,079 | |||
EV | 343,684 | 127,115 | 159,565 | |||
EBITDA | (13,872) | (9,144) | (5,810) | |||
EV/EBITDA | ||||||
Interest | 34 | 32 | 23 | |||
Interest/NOPBT | ||||||